Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 08:50 am Sale |
2023-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
Deep Track Capital, LP | 0 0.000% |
-4,259,653 (Position Closed) |
Filing History |
| 2024-02-09 4:05 pm Sale |
2023-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
Opaleye Management Inc. | 0 0.000% |
-2,810,000 (Position Closed) |
Filing History |
| 2024-02-02 12:28 pm Sale |
2023-12-29 | 13G | Jounce Therapeutics, Inc. JNCE |
Cowen Financial Products LLC | 0 0.000% |
-3,647,430 (Position Closed) |
Filing History |
| 2023-05-05 4:34 pm Sale |
2023-05-03 | 13D | Jounce Therapeutics, Inc. JNCE |
TANG CAPITAL PARTNERS LP | 10,000 100.000% |
-5,290,087 (-99.81%) |
Filing History |
| 2023-04-12 4:15 pm Purchase |
2022-03-30 | 13G | Jounce Therapeutics, Inc. JNCE |
Opaleye Management Inc. | 2,810,000 5.390% |
2,810,000 (New Position) |
Filing History |
| 2023-04-07 4:00 pm Unchanged |
2023-04-05 | 13D | Jounce Therapeutics, Inc. JNCE |
TANG CAPITAL PARTNERS LP | 5,300,087 10.200% |
0 (Unchanged) |
Filing History |
| 2023-03-28 4:00 pm Unchanged |
2023-03-26 | 13D | Jounce Therapeutics, Inc. JNCE |
TANG CAPITAL PARTNERS LP | 5,300,087 10.200% |
0 (Unchanged) |
Filing History |
| 2023-03-17 4:00 pm Unchanged |
2023-03-17 | 13D | Jounce Therapeutics, Inc. JNCE |
TANG CAPITAL PARTNERS LP | 5,300,087 10.200% |
0 (Unchanged) |
Filing History |
| 2023-03-14 5:00 pm Purchase |
2023-03-14 | 13D | Jounce Therapeutics, Inc. JNCE |
TANG CAPITAL PARTNERS LP | 5,300,087 10.200% |
300,087 (+6.00%) |
Filing History |
| 2023-03-06 4:00 pm Purchase |
2023-02-23 | 13G | Jounce Therapeutics, Inc. JNCE |
TANG CAPITAL PARTNERS LP | 5,000,000 9.700% |
5,000,000 (New Position) |
Filing History |
| 2023-02-14 4:30 pm Sale |
2022-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
ORBIMED ADVISORS LLC | 0 0.000% |
-2,200,200 (Position Closed) |
Filing History |
| 2023-02-14 4:06 pm Sale |
2022-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
PFM Health Sciences, LP | 345,926 0.700% |
-3,626,942 (-91.29%) |
Filing History |
| 2023-02-14 4:06 pm Sale |
2022-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
Third Rock Ventures II L.P. | 335,533 0.600% |
-3,794,934 (-91.88%) |
Filing History |
| 2023-02-14 10:07 am Purchase |
2022-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
RTW Investments, LP | 5,106,341 9.900% |
2,243,143 (+78.34%) |
Filing History |
| 2023-02-14 08:40 am Purchase |
2022-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
Deep Track Capital, LP | 4,259,653 8.240% |
259,653 (+6.49%) |
Filing History |
| 2023-02-14 08:23 am Purchase |
2022-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
BANK OF AMERICA CORP BAC |
3,276,699 6.300% |
3,276,699 (New Position) |
Filing History |
| 2023-01-23 3:48 pm Purchase |
2022-12-30 | 13G | Jounce Therapeutics, Inc. JNCE |
Cowen Financial Products LLC | 3,647,430 7.050% |
567,078 (+18.41%) |
Filing History |
| 2022-04-22 10:54 am Purchase |
2022-04-21 | 13G | Jounce Therapeutics, Inc. JNCE |
Cowen Financial Products LLC | 3,080,352 5.960% |
3,080,352 (New Position) |
Filing History |
| 2022-02-14 4:52 pm Sale |
2021-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
Third Rock Ventures II L.P. | 4,130,467 8.100% |
-8,209,361 (-66.53%) |
Filing History |
| 2022-02-14 12:37 pm Purchase |
2021-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
PFM Health Sciences, LP | 3,972,868 7.800% |
1,584,801 (+66.36%) |
Filing History |